DSIP
DSIP (Delta Sleep-Inducing Peptide) is a 9-amino-acid neuropeptide studied for deep-sleep and circadian support; research protocols typically use 75 mcg subcutaneously daily 30-60 minutes before bed (titrating toward 300 mcg).
Best for
Adults with sleep-architecture concerns (particularly those who fall asleep easily but wake frequently) or stress-related sleep disruption that doesn't respond to sleep hygiene alone
What to expect
Sleep quality changes typically reported within the first 1-2 weeks of consistent use
Pairs with
Often standalone for sleep. Some protocols pair with Sermorelin or similar GHRH peptides for nighttime GH-pulse alignment
Subcutaneous injection 30-60 minutes before bed. Typical research dose 0.1-0.3mg; many protocols cycle 5 days on, 2 off to avoid receptor desensitization
- How often
- Daily
- When
- Bedtime
- Route
- Subcutaneous
- Vial & water
- 5 mg vial in 3 mL = 1.67 mg/mL · 75 mcg = 4.5 units on a U-100 syringe
- Cycle
- Often 5-on/2-off (mainly to stretch cost) or nightly — your call. Start 75 mcg to assess tolerance.
The same numbers the goodtides app and the Dose Calc use — a research reference, not a prescription. Responses are individual; research protocols start at the low end.
DSIP (Delta Sleep-Inducing Peptide) is a 9-amino-acid neuropeptide first isolated in 1977 from the cerebral venous blood of rabbits during induced slow-wave sleep.
Researchers have since characterized DSIP-responsive sites throughout the brain (particularly in the hypothalamus, limbic system, and brainstem) and shown that exogenous administration can increase slow-wave (delta) sleep duration and reduce sleep latency in some research populations. Unlike sedative-hypnotics (benzodiazepines, Z-drugs), DSIP appears to act through endogenous sleep-regulation pathways rather than direct GABA-A receptor agonism, which is why it doesn't produce the next-day grogginess characteristic of conventional sleep medications.
Soviet and Russian research groups studied DSIP extensively across the 1980s and 1990s, not only for sleep but for stress adaptation, chronic pain, and opiate withdrawal, where its anti-stress properties were documented in animal and small human cohorts. More recent work investigates potential roles in neuroprotection, circadian regulation, and corticotropin-releasing hormone (CRH) modulation.
Because DSIP doesn't have a single well-defined receptor in the conventional drug-target sense, the precise mechanism remains an active research question. Current hypotheses focus on CRH modulation, serotonin pathway interactions, and direct effects on sleep-spindle generation in the thalamus.
- Half-life
- ~15 min in vitro (rapid aminopeptidase degradation)
- Peak
- Reported within ~1-2 h of administration in research
- Absorption
- Rapidly degraded by peptidases; parenteral routes used in research
- Bioavailability
- Low oral bioavailability; studied via injection/IV
References4
- Schneider-Helmert D, Schoenenberger GA - The influence of synthetic DSIP (delta-sleep-inducing peptide) on disturbed human sleep (Experientia)
- Kovalzon VM et al. - Delta sleep-inducing peptide (DSIP): a still unresolved riddle (J Neurochem)
- Schoenenberger GA et al. - The delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptide (Pflugers Arch)
- PubChem - Delta sleep-inducing peptide Compound Summary, CID 68816 (sequence WAGGDASGE, C35H48N10O15, MW 848.8)
Log every dose, count every vial, and verify your batches — free in the goodtides app.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.